European biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned DOI Creative Commons
Diego M. Conti, Vibeke Backer,

W.J. Fokkens

et al.

Frontiers in Allergy, Journal Year: 2024, Volume and Issue: 5

Published: Dec. 12, 2024

The European Forum for Research and Education in Allergy Airways diseases (EUFOREA) organized the first Biologic Training Course (EBTC) Brussels on 1st March 2024. aim of this hybrid EBTC including both face-to-face web-based participation was to address educational needs physicians dealing with asthma Chronic Rhinosinusitis Nasal Polyps (CRSwNP) clinically relevant aspects diagnosing treatment biologics. EUFOREA is an international non-for-profit organization forming alliance all stakeholders dedicated reducing prevalence burden chronic respiratory through implementation optimal patient care via educational, research, advocacy activities. inclusive multidisciplinary approach reflected faculty coming from paediatric, allergology, pulmonology, Ear, Nose Throat (ENT) speciality different continents, more than 250 participants over 30 countries EBTC. current report provides a comprehensive overview key statements made by 2024, especially focusing selection biologic drug, communication patients, onset biological follow-up routine clinical practice.

Language: Английский

EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR DOI Creative Commons

G. K. Scadding,

Diego M. Conti, Sophie Scheire

et al.

Frontiers in Allergy, Journal Year: 2025, Volume and Issue: 5

Published: Feb. 3, 2025

Allergic rhinitis (AR), the most prevalent immunological disease, affects approximately 400 million individuals globally and can significantly impact quality of life (QoL). Despite nearly 25 years guidelines, AR remains largely under- diagnosed, suboptimally treated poorly controlled. In light new knowledge treatment options, there is a necessity to update or revise fundamental definitions facilitate communication across diverse specialties engaged in its improve patient care. The European Forum for Research Education Allergy Airway Diseases (EUFOREA) convened meeting experts representatives deliberate optimal methodology measuring responses establishing novel goals. This paper presents consensus on revised definitions, including control, severe allergic rhinoconjunctivitis (SARC), refractory (R-SARC), remission, resolution, improvement, exacerbation, treatable traits (TTs), treat target, relapse, progression, disease modification, prevention.

Language: Английский

Citations

0
Raising the bar in respiratory care by EUFOREA: report of the European Union Parliament Symposium, April 2024 DOI Creative Commons
Peter W. Hellings, Diego M. Conti, Xander Bertels

et al.

Frontiers in Allergy, Journal Year: 2025, Volume and Issue: 6

Published: Feb. 24, 2025

In April 2024, the European Summit "Raising bar in respiratory care" was organized by Forum for Research and Education Allergy Airway Diseases (EUFOREA) Parliament hosted Members of Dorien Rookmaker Mislav Kolakušić. The aim to respond need patients suffering from chronic diseases (CRDs) joining forces with global organisations management epidemics CRD, recognising weaknesses current care models focussing on collaboration improve prevention. Participants belonging International National Societies Committees Rhinologic Society (ERS), (IRS), Belgian Respiratory (BeRS), Global Initiative Asthma (GINA), Chronic Obstructive Lung Disease (GOLD), Alliance against (GARD), Federation Airways Patients Associations (EFA) EUFOREA's Patient Advisory Board (PAB) described their vision action plan work partnership raise care. This report summarizes contributions representatives different stakeholders field CRDs.

Language: Английский

Citations

0
Pre-asthma: a useful concept? A EUFOREA paper. Part 2—late onset eosinophilic asthma DOI Creative Commons
Glenis Scadding, Claudia L. Gray, Diego M. Conti

et al.

Frontiers in Allergy, Journal Year: 2024, Volume and Issue: 5

Published: May 15, 2024

The concept of pre-diabetes has led to provision measures reduce disease progression through identification subjects at risk diabetes. We previously considered the idea pre-asthma in relation allergic asthma and that, addition need improve population health via multiple measures, including reduction exposure allergens pollutants avoidance obesity, there are several possible specific means development those most (pre- asthma). obvious is allergen immunotherapy (AIT), which when given for rhinitis (AR) reasonable evidence support prevention children (2) but also needs further study as primary prevention. In this second paper we explore possibilities similar actions late onset eosinophilic asthma.

Language: Английский

Citations

2
EUFOREUM Berlin 2023: Optimizing care for type 2 inflammatory diseases from clinic to AI: A pediatric focus DOI Creative Commons
Diego M. Conti, Vibeke Backer,

Beyer Kirsten

et al.

Pediatric Allergy and Immunology, Journal Year: 2024, Volume and Issue: 35(7)

Published: July 1, 2024

Abstract The European Forum for Research and Education in Allergy Airways diseases (EUFOREA) organized its bi‐annual forum EUFOREUM Berlin November 2023. aim of 2023 was to highlight pediatric action plans prevention optimizing care type 2 inflammatory conditions starting childhood, with a focus on early‐stage diagnosis, ensuring neither under‐ nor overdiagnosis, optimal care, suggestions improvement care. EUFOREA is an international not‐for‐profit organization forming alliance all stakeholders dedicated reducing the prevalence burden chronic respiratory through implementation patient via educational, research, advocacy activities. inclusive multidisciplinary approach reflected keynote lectures faculty virtual ( www.euforea.eu/euforeum ) coming from pediatric, allergology, pulmonology, ENT, dermatology, primary health fields patients around central theme inflammation. As most may start childhood or adolescence, children have inflammation when suffering skin disease, moment has come raise bar ambitions including prevention, remission disease modification at early stage. current report provides comprehensive overview key statements by allowing field be updated ready join forces Europe beyond. image

Language: Английский

Citations

2
European biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned DOI Creative Commons
Diego M. Conti, Vibeke Backer,

W.J. Fokkens

et al.

Frontiers in Allergy, Journal Year: 2024, Volume and Issue: 5

Published: Dec. 12, 2024

The European Forum for Research and Education in Allergy Airways diseases (EUFOREA) organized the first Biologic Training Course (EBTC) Brussels on 1st March 2024. aim of this hybrid EBTC including both face-to-face web-based participation was to address educational needs physicians dealing with asthma Chronic Rhinosinusitis Nasal Polyps (CRSwNP) clinically relevant aspects diagnosing treatment biologics. EUFOREA is an international non-for-profit organization forming alliance all stakeholders dedicated reducing prevalence burden chronic respiratory through implementation optimal patient care via educational, research, advocacy activities. inclusive multidisciplinary approach reflected faculty coming from paediatric, allergology, pulmonology, Ear, Nose Throat (ENT) speciality different continents, more than 250 participants over 30 countries EBTC. current report provides a comprehensive overview key statements made by 2024, especially focusing selection biologic drug, communication patients, onset biological follow-up routine clinical practice.

Language: Английский

Citations

0